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Abstract
Serhan and colleagues introduced the term “Resoleomics” in 1996 as the process of inflammation resolution. The
major discovery of Serhan’s work is that onset to conclusion of an inflammation is a controlled process of the
immune system (IS) and not simply the consequence of an extinguished or “exhausted” immune reaction.
Resoleomics can be considered as the evolutionary mechanism of restoring homeostatic balances after injury,
inflammation and infection. Under normal circumstances, Resoleomics should be able to conclude inflammatory
responses. Considering the modern pandemic increase of chronic medical and psychiatric illnesses involving
chronic inflammation, it has become apparent that Resoleomics is not fulfilling its potential resolving capacity. We
suggest that recent drastic changes in lifestyle, including diet and psycho-emotional stress, are responsible for
inflammation and for disturbances in Resoleomics. In addition, current interventions, like chronic use of anti-
inflammatory medication, suppress Resoleomics. These new lifestyle factors, including the use of medication,
should be considered health hazards, as they are capable of long-term or chronic activation of the central stress
axes. The IS is designed to produce solutions for fast, intensive hazards, not to cope with long-term, chronic
stimulation. The never-ending stress factors of recent lifestyle changes have pushed the IS and the central stress
system into a constant state of activity, leading to chronically unresolved inflammation and increased vulnerability
for chronic disease. Our hypothesis is that modern diet, increased psycho-emotional stress and chronic use of anti-
inflammatory medication disrupt the natural process of inflammation resolution ie Resoleomics.
Keywords: Chronic inflammation, Central stress system, Nutrition, Resoleomics, Sympathetic-adrenal-medulla axis,
Hypothalamus-pituitary-adrenal axis, Anti-inflammatory medication, Insulin resistance, Polyunsaturated fatty acids,
Glycemic index
Introduction
T h en u m b e ro fp e o p l es u f f e r i n gf r o mc h r o n i cd i s e a s e s
such as cardiovascular diseases (CVD), diabetes, respira-
tory diseases, mental disorders, autoimmune diseases
(AID) and cancers has increased dramatically over the
last three decades. The increasing rates of these chronic
systemic illnesses suggest that inflammation [1,2],
caused by excessive and inappropriate innate immune
system (IIS) activity, is unable to respond appropriately
to danger signals that are new in the context of evolu-
tion. This leads to unresolved or chronic inflammatory
activation in the body.
Inflammation is designed to limit invasions and
damage after injury, a process which has been essential
for the survival of Homo sapiens in the absence of med-
ication such as antibiotics. Recently, it has been discov-
ered that onset to conclusion of an inflammation is a
self-limiting and controlled process of the immune sys-
tem (IS). This process of inflammation resolution is
defined by Serhan as Resoleomics [3], a term which will
be used throughout this article.
Our genes and physiology, which are still almost identi-
cal to those of our hunter-gatherer ancestors of 100,000
years ago, preserve core regulation and recovery processes
[4,5]. Nowadays our genes operate in an environment
which is completely different to the one for which they
were designed.
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changed enormously since the time of the industrial
revolution. In recent decades there has been a tremen-
dous acceleration in innovations which have changed
our lives completely. As a consequence, more than 75%
of humans do not meet the minimum requirement of
the estimated necessary daily physical activity [6], 72%
of modern food types is new in human evolution [7],
psycho-emotional stress has increased and man is
exposed to an overwhelming amount of information on
a daily basis. All these factors combine to produce an
environment full of modern danger signals which con-
t i n u o u s l ya c t i v a t et h eI I Sa n d central stress axes. The
question is whether the IIS and its natural inflammatory
response, Resoleomics, can still function optimally in
this modern, fast-changing environment, considering
that the IIS is designed to produce short, intensive reac-
tions to acute external danger [8,9]. It would seem that
in the bodies of people who have adopted a Western
lifestyle the inflammatory response is not concluded
because of an initial excessive or subnormal onset of the
response [10].
This article postulates how triggers from chronic
altered diet and psycho-emotional stress negatively
influence Resoleomics, thereby increasing susceptibility
to the development of chronic, low-grade, inflamma-
tion-based diseases due to the constant activation of
both the central stress axes and the IIS. In addition, an
attempt is made to demonstrate the ways in which the
use of anti-inflammatory medication could influence
Resoleomics.
Resoleomics, a self-limiting process of
inflammation
Serhan and his colleagues [3] introduced the term Reso-
leomics to describe a self-limiting process of inflammation,
executed and controlled by the innate immune system
(IIS) and regulated by the sympathetic nervous system
(SNS) and the hypothalamus-pituitary-adrenal (HPA) axis.
This process controls inflammation using metabolites pro-
duced from arachidonic acid (AA), eicosapentaenoic acid
(EPA) and docosahexenoic acid (DHA). Resoleomics oper-
ates locally when polymorphonuclear neutrophils (PMNs)
are attracted by increased pro-inflammatory cytokine and
eicosanoids production during microbial invasion, wound
healing or chemical injury. The function is to limit the
inflammation response. The central control system of the
inflammatory reaction is very complex. Local and central
processes influence each other and both are responsible
for an optimal resolving response (Figure 1). The local
process can be divided into three phases [11] (Figure 2):
1. Initiation phase
2. Resolution phase
3. Termination phase
Initiation phase
Pro-inflammatory eicosanoids, like leukotrienes B4
(LTB4) and prostaglandins (PGs) initiate the inflamma-
tory response. PMNs generate LTB4 and PGE2 from
precursor AA with the use of lipoxygenase-5 (LOX-5)
and cyclo-oxygenase 2 (COX-2). Both eicosanoids
enhance inflammation, LTB4 being the strongest che-
motoxic compound of cytotoxic neutrophils. PGE2 and/
or PGD2, although initially pro-inflammatory, determine
the switch to the next phase, the resolution of the
inflammation.
Resolution phase
This phase starts with the Eicosanoid Switch to resolution.
When the PGE2 and/or PGD2 level is equal to the level of
LTB4, the PMNs activate the switch from pro-inflamma-
tory to anti-inflammatory eicosanoids production by limit-
ing the production of LOX-5. This switch is responsible
for the production of anti-inflammatory lipoxins (LXs)
from AA through activation of lipoxygenase -12 (LOX-
12), lipoxygenase-15 (LOX-15) and acetylated COX-2
[13,14]. This last mechanism has been found to be respon-
sible for the production of more stable aspirin-triggered
LXs (ATLs) with a longer half-value period [15]. Other
resolving metabolites that support LXs are resolvins,
(neuro)protectins and maresins produced from respec-
tively EPA and DHA [11,16]. A second substantial increase
of COX-2 activity will produce anti-inflammatory PGs
(PGD2 and PGF2a) during this phase [17].
Termination phase
This phase starts when the Stop Signal takes place. This
happens when sufficient anti-inflammatory mediators
such as LXs are available to stop the pro-inflammatory
process [13,14]. LXs are capable of inhibiting both PMN
infiltration and the activity of cytotoxic cells of the ISS,
inducing phagocytosis to clear debris by non-cytoxic
macrophages and attenuating an accumulation of the pro-
inflammatory transcription factors, ie nuclear factor-
kappaB (NF-kB) and activator protein 1 (AP-1) [18,19].
Central stress axes and Resoleomics
This section deals solely with the effect of the sympathetic,
parasympathetic and the HPA axis on Resoleomics. The
systemic stress system is closely linked to the IIS via the
stress axes of our body. Anything that can activate the
sympathetic-adrenal-medulla (SAM) and HPA axes will
have its effect on the IIS [20] and therefore on Resoleo-
mics. Seen in reverse, it is precisely the IIS that can trigger
stress axes, inducing a systemic stress reaction in the body
[21]. In the SNS, which initially activates the IIS, inhibition
of the IIS is provided by the strong anti-inflammatory neu-
rotransmitter acetylcholine (ACh), produced by the para-
sympathetic nervous system [22].
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Activation of the SAM axis is considered the first wave,
giving rise to the excretion of brain norepinephrine (NE)
by the Locus Coeruleus (LC). The descending pathway
activates sympathetic motor neurons in the medulla
oblongata, which stimulate the adrenal glands (through
sympathetic efferent nerves). The adrenal gland will now
excrete catecholamines, which activate and induce prolif-
eration of ISS cells. NF-kB increases pro-inflammatory
cytokines production, such as interleukin 1-beta (IL1-b),
interleukin 6 (IL-6) and tumor necrosis factor (TNF). Both
the IIS and Th1 of the adaptive IS contain receptors sensi-
tive to catecholamines. Cerebral catecholamines affect the
activity of spleen, thymus, bone marrow and lymphoid
nodes [23]. NE has been shown to activate the IIS at the
onset of inflammation, while long-term activation of the
SNS induces IIS inhibition [24].
The second wave of the systemic stress reaction corre-
sponds with the activation of the HPA axis, with gluco-
corticoids (GCs) as end product. Cortisol is capable of
inhibiting the IIS through the upward regulation of inhi-
biting factor kappa B (IkB), while informing the immu-
nological cortex through the migration of different
immune cells to the brain [25,26]. Cortisol, the regulator
of the IIS response, can guide the inflammation into
resolution phase. Termination is instigated when cortisol
“overrules” the NE effect on NF-kB signalling through
genetic influence and reduction of transcription of the
NF-kB sensitive pro-inflammatory gene, resulting in the
finalization of the inflammatory response (Figure 2).
 
Figure 1 Start and finish of a physiological inflammatory reaction in wound healing and situations of microbial challenge. Cellular
damage and leakage of alarmins attract neutrophils to the damaged area (PMN’s). Sympathetic afferents activate the locus coeruleus (central
nucleus of the sympathetic nervous system, SNS) and Noradrenaline (Norepinephrine, NE) is released. The released NE activates the adrenal
medulla inducing the production of systemic catecholamins that supports the activation of the PMN. Damaged blood vessels are a source of an
omega 3 rich edema (EPA and DHA). DHA and EPA inhibit LOX-5 directly and through conversion into resolvins and protectins. Both PGE2 and
PGD2, produced by the breakdown of AA by COX-2 activity, will now override the strong chemotaxic effect of LTB4. The combined action of
protectins, resolvins and lipoxins produced out of AA will put a hold on the pro-inflammatory activity of PMN’s, which is supported by the
increased production of systemic cortisol. Cortisol further activates macrophages (M-Ph) to phagocytose issue debris and quiet PMN by releasing
substances such as LXA4, resolvin E1 (RvE1), prostanoid D1 (PD1), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF) and
epithelial growth factor (EGF) at the same time. Further edema leakage will be stopped, whereas angiogenesis and production of connective
tissue will take place, finishing the inflammatory reaction and starting the production of new tissue.
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ported by a compensatory anti-inflammatory response
through activation of the vagal anti-inflammatory loop
[27]. The resulting production of ACh inhibits the IS
through the alfa-7-nicotin-Acetylcholinergic Receptor
(a7nAChR) [28] (Figure 1).
The SNS (NE) increases the initial pro-inflammatory
immune response in the initiation phase, whereas
delayed cortisol response, induced by the HPA axis,
inhibits the pro-inflammatory response [29]. Integrity of
the SAM axis with its NE response/reaction is necessary
for an adequate initial inflammatory response [30]. At
the beginning of the initiation phase, there is resistance
to both cortisol and insulin in order to allow for the
activation of the IIS [12]. At the end of this phase, corti-
sol sensitivity and insulin sensitivity should be recovered
to facilitate the Eicosanoid Switch to the resolution
phase.
Chronic stress exposure reduces the capacity to mount
an acute stress response [31], resulting in an inadequate
pro-inflammatory response. Chronic (psycho-emotional)
stress situations can be responsible for the continuous
production of catecholamines by the SAM axis. People
suffering from “perpetual stress”, for example the parents
of a child with cancer, showed chronic, increased levels
of circulating pro-inflammatory cytokines [26]. This
situation requires a high level of energy expenditure. The
metabolic rate is increased to provide extra energy for
the brain (arousal of all senses), the heart muscle and the
locomotive system. The existing cells from the IIS are
activated and will proliferate (relatively low energy
expenditure), whereas proliferation of new immune cells
(much more costly energy expenditure) will be blocked.
Further consequences of chronic SAM activity are nar-
rowing of the cell spectrum of the IIS and complete loss
of activity of the Th1 section of the adaptive IS, leading
to an insufficient capability to fight viruses, (pre)neoplas-
tic cells and intracellularly presented pathogens [31].
An inflammatory response leading to solution depends
on the sensitivity of glucocorticoid receptors (GR) and
catecholamine receptors of the IIS [32]. Factors such as
stress endured early in life, trauma and polymorphisms
are possible risk factors for loss of GR and catecholamine
sensitivity [33-35].
Suboptimal inflammatory response as a consequence of
chronic stress prevents the Eicosanoid Switch from func-
tioning, since the switch to the resolution phase requires
recovered cortisol and insulin sensitivity. The initiation
phase should have a maximum duration of 8 to 12 hrs.
PMN number and activation levels should reach their
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Figure 2 Inflammation is a controlled process with an initiation, resolution and termination phase. After microbial invasion, lesion or
chemical injury, the initiation phase starts with the production of pro-inflammatory mediators like LTB4 and PG2. These mediators increase
inflammation until the Eicosanoid Switch, the end of the initiation phase, takes place. This occurs when the level of PGE2 plus PGD2 is equal to
the LTB4 level. The resolution phase is entered, triggering the generation of anti-inflammatory mediators like LK, resolvins, protectins, maresins,
PGD2 and PGF2a. When the total level of anti-inflammatory mediators exceeds the level of LTB4 the Stop Signal takes place. This is the last
phase, the inflammation will be terminated by clearing the affected area [11]. The stress hormones produced by the systemic stress axes have a
direct effect on the inflammation phases. A microbial invasion, lesion or injury sends off an alarm in the body, setting off the systemic stress
system which produces NE as response and tunes the system to insulin and cortisol resistance [12]. The Eicosanoids Switch to resolution can
only take place when NE is equal to the level of cortisol plus insulin and when cortisol sensitivity is recovered. The Stop Signal requires a low
level of NE and normalized cortisol sensitivity. The termination phase is entered when the stress axes are switched off.
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chronic stress could produce secondary damage to neigh-
bouring tissues due to the strong cytotoxic effects of acti-
vated PMNs [11]. Supramaximal activation of PMNs
could sensitize the adapted IS if contact time between
self-antigens and the IS is significantly increased [11,29].
The crosstalk between the IS and stress axes is further
evidenced by the fact that acute production of high levels
of catecholamines activate the IIS strongly [23], whereas
eicosanoids produced from AA induce the production of
local and systemic catecholamines [36]. Long-term activa-
tion may lead to catecholamine resistance and lack of eico-
sanoid production. This situation, combined with the
aforementioned possibility of resistance to insulin and cor-
tisol, provokes a suboptimal inflammatory response and
consequently the perpetuation and development of low-
grade inflammation [26,37].
Nutritional factors and Resoleomics
Several dietary factors influence the activity of the IIS and
the function of a wide range of hormones, including cor-
tisol, insulin and catecholamines. The dramatic changes
in dietary composition since the agricultural revolution
(some 10,000 years ago) and, to a greater extent, since
the industrial revolution (some 200 years ago) have
turned the intake of food into a common daily danger
and therefore a cause of continuous systemic stress.
Some of these changes include an increase in the omega
6/omega 3 fatty acid ratio, a high intake of saturated fatty
acids (SFA) and refined carbohydrates, the introduction
of industrially produced trans fatty acids, a lower intake
of vitamins D and K, imbalanced intake of antioxidants,
high intake of anti-nutrients (eg lectines, saponins) and
an altered intake of dietary fibre [38].
The following section will discuss the impact of the
changed ratio of polyunsaturated fatty acids (PUFAs) and
the intake of food with a high glycemic load on Resoleo-
mics. The pro-inflammatory effects of anti-nutrients pre-
sent in cereals [39], potatoes [40], legumes [41], and
tomato have previously been extensively reviewed [7].
Role of PUFAs in inflammation
The intake ratio of a-linoleic acid (LA) (omega 6), a-lino-
lenic acid (ALA) (omega 3), docosahexaenoic acid (DHA)
and eicosapentaenoic acid (EPA) in the Western diet has
changed dramatically compared to the estimated intake
ratio of hunter-gatherer diets from 2-3:1 to 10-20:1 in the
contemporary diet [42,43]. All of these PUFAs are essen-
tial for normal Resoleomics response, as they function as
precursors for the special small mediators responsible for
the instigation and conclusion of the inflammatory
response. One of the toxic changes in fatty acid composi-
tion of food corresponds to the increased intake of LA
since the production of vegetable oils in 1913. Increased
LA levels affect the inflammation process in three ways
(Figure 3):
1. Increase of the omega 6/omega 3 fatty acid ratio
2. Altered AA level
3. Increases of inflammatory compounds, leukotoxins
(LK) production
Increased omega 6/omega 3 fatty acid ratio
The inflammatory effect of a high omega 6/omega 3 fatty
acid ratio during inflammation has been demonstrated in
recent human studies [44,45], in vitro studies [46,47] and
animal studies [48,49]. The higher LA levels in phospholi-
pids in plasma and cell membranes seem to be a major
factor responsible for incomplete Resoleomics reactions.
Higher intake of omega 3 fatty acids in the form of DHA
and EPA regulate the production of pro-inflammatory
cytokines and decrease LA levels in phospholipids in
plasma and cell membranes [46,48]. The conversion of LA
and ALA into respectively AA, DHA and EPA depend on
the same enzymes in the desaturase and elongase cascade,
with δ-6-desaturase as the rate-limiting enzyme (Figure 4)
[50].
Human trials investigating the effects of omega 3 dietary
supplements showed significant improvements of symp-
toms in patients suffering from diseases such as RA,
inflammatory bowel disease, asthma, psoriasis, breast can-
cer and CVD. However, full remission of symptoms was
not achieved [43,51]. Our conclusion is that an increased
intake of omega 3 alone is not enough to restore Resoleo-
mics; the intake of LA must be decreased as well.
LA effect on AA level
Higher AA levels in plasma result in more adequate
inflammatory reactions, since AA is a precursor of pro-
and anti-inflammatory substances within the self-limiting
inflammatory process [52]. LA is the precursor for AA in
the desaturase/elongase conversion (Figure 4). Theoreti-
cally, LA could be the source of a sufficient level of endo-
genous AA. However, higher intake of LA does not deliver
increased levels of AA in comparison to low intake
[53,54]. To achieve the required AA level, AA should be
present in the regular diet [45]. The combined situation of
AA deficiency together with a reduced intake of omega 3
fatty acids such as DHA and EPA (necessary for the flip
flop reaction of LOX-5 and the Eicosanoid Switch [3]),
enable a perpetuation of the pro-inflammatory initiation
phase and therefore of chronic inflammation.
Increased production of leukotoxin
The third harmful effect of high LA intake is the possible
production of so-called leukotoxins (LK). High LA levels
are metabolized by CYP2C9 in the liver into biologically
active oxidation products known as LK and leukotoxin
diol (LTD). These metabolites promote oxidative stress
responses and the activation of NFkB and AP-1, increasing
the systemic release of pro-inflammatory cytokines [55].
LK and LTD are toxic for T cells, and can kill these cells
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death [56].
Role of high glycemic food in Inflammation
An abundant intake of high glycemic food appears to be
related to an increased susceptibility to the development
of chronic inflammation, as has been demonstrated by sev-
eral research groups [57-59]. The consequences of a high
carbohydrate diet are complex and multiple. The pathways
leading to disturbances of normal inflammation are:
1. High glycemic food intake increases inflammation
markers
2. High glycemic food intake causes hyperglycemia
and hyperinsulinemia leading to disturbed balances in
insulin growth factor-1 (IGF-1) and androgens
3. Chronic intake of high glycemic food causes hypo-
glycemia, which triggers central stress axes
High Glycemic food increases inflammation markers
Various clinical trials have shown that an abundant intake
of high glycemic food increases inflammatory markers and
markers of metabolic syndrome such as postprandial NFkB
in mononuclear cells [57], high sensitive-C-Reactive Pro-
tein (hs-CRP)[58], interleukin (IL)-6, IL-7, IL-18 [60], levels
of free radicals [59], cholesterol, triglycerides [61] and even
blood pressure [62]. Changes incurred by following a low
glycemic diet include improved insulin sensitivity, lower
blood pressure and total cholesterol, which are all key mar-
kers of the metabolic syndrome [58,60,61]. The high glu-
cose-induced inflammatory response is accompanied by
hyperinsulinemia and insulin resistance, characteristic for
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Page 6 of 14people suffering from obesity [57,59]. Increased hsCRP
values, hyperinsulinemia and insulin resistance are strongly
related to CVD risk [60]. Glycemic index (GI) and glycemic
load (GL) have therefore been proposed as biomarkers and
predictors for (chronic) inflammation [63].
Hyperglycemia and hyperinsulinemia
Cordain demonstrated that high glycemic food is a poten-
tial risk factor for inflammation through disturbed signal-
ling of mechanisms as a result of hyperglycemia and
hyperinsulinemia [64] (Figure 5b). Long exposure to high
glucose levels in blood, which leads to a slow recovery of
the homeostasis, makes tissues vulnerable to disease [65].
High plasma insulin can increase the production of IGF-1
and androgens. Both hormones are related to disorders
such as polycystic ovarian syndrome (PCOS) [66], epithe-
lial cell cancer (breast, prostate, colon) [67,68], acne [69],
androgenic alopecia [70], and acanthosis nigricans [71].
Several pathways in this respect have been previously
described in medical literature, but these go beyond the
scope of this article.
Hypoglycemia triggers the systemic stress system
As previously mentioned, intake of a high glycemic diet
can cause hyperglycemia and hyperinsulinemia. Hyper-
glycemia will push abundant glucose via insulin into
muscle and adipocytes at the instigation of the inflam-
matory process. However, continuous intake of high gly-
cemic food results in reactive hypoglycemia, ie an
energy-deficient situation which threatens the homeosta-
sis of the body. As a consequence, the brain will main-
tain its own energy supply aimed at the survival of the
organism (the selfish brain) [25]. To ensure sufficient
energy supply, the brain activates its systemic stress sys-
tem to induce gluconeogenesis (Figure 5a). Excreted
catecholamines and cortisol will mobilize extra energy,
which is allocated with priority to the brain and to the
activated IS, at the expense of other body tissues [72].
On the basis of the above information and other refer-
enced data, it seems plausible to state that aspects of the
Western diet, of the modern industrialised environment
and of their resultant lifestyles form a chronic danger to
the body, triggering both the central stress axes and the
IIS into a state of chronic activity. This state seems to be a
direct cause of the development of low-grade inflamma-
tion and consequently of chronic inflammatory diseases
(Figure 5a).
Impact of current medication on Resoleomics
The role of the IIS is to limit the damage of inflamma-
tion in acute situations. Anti-inflammatory medication
can be used to dampen the immune response. Nowa-
days, as a result of lifestyle changes, man is exposed to
chronic inflammation and consequently to the chronic
use of anti-inflammatory medication, much of which in
fact suppresses Resoleomics. Current medication used to
treat chronic inflammatory diseases does suppress the
symptoms of inflammation, but complete remission of
the disease is seldom realized [73]. Resoleomics is hin-
dered and complete resolution of the inflammation does
not take place. Modern chronic inflammatory diseases
are treated by several groups of medication. In this arti-
cle we focus on rheumatoid arthritis (RA) medication as
an example. Four groups of anti-inflammatory RA medi-
cation are taken into account: the prostaglandin inhibi-
tors [Nonsteroidal anti-inflammatory drugs [NSAIDs:
Aspirin (ASA) and COX-inhibitors], the Glucocorticoids
(GCs), the Disease Modifying Drugs [DMARDs: Metho-
trexate (MTX) and Sulfasalazine (SSZ)] and the cytokine
blockers [Biologicala g e n t s :a n t iT N F - alpha and IL-1
blockers]. The mechanisms of action and possible effects
on the IIS and Resoleomics are summarized from litera-
ture (see Table 1). Most current therapies target the IIS
in an attempt to inhibit the production of pro-inflam-
matory chemical mediators (Table 1). However, an
equally important target is the active induction of pro-
resolution programs by stromal cells such as fibroblasts
within the inflamed tissues [74]. Inhibition of MIF [75]
and production of NO [76] are not addressed in this
article.
Positive effect of ASA and GCs on Resoleomics
Medical intervention should stimulate the endogenous
pathways of resolution and two drugs already known to
possess these qualities are central to contemporary
medicine: glucocorticoids (GCs) [77] and aspirin (ASA)
[106,107]. It is apparent that ASA and GCs have a
positive effect on Resoleomics, while other medications
prolong the initiation phase, tempering and/or blocking
the resolution and termination phase of Resoleomics in
various ways (Table 1). The positive effect of ASA on
Resoleomics can be ascribed to its ability to produce
ASA-triggered lipoxins (ATLs) through acetylation
(and not through an irreversible inhibition) of the
COX-2 enzymes [78]. These ATLs show many pro-
resolving properties, which are essential in the resolu-
tion and termination phase of the inflammation pro-
cess [79,108]. Long-term intake of high doses of ASA
blocks PGE2 production and initiates the resolution
phase without affecting the biosynthesis of other pro-
resolving mediators [108]. Low and high doses of ASA
increase the production of lipoxin A4 (LXA4) and 15-
epi-LXA4 in the rat brain, suggesting that ASA could
protect against neuroinflammation [109]. However,
because of its side effects, ASA is no longer the treat-
ment of choice for RA. In high doses, inhibition of the
C O X - 1e n z y m eb yA S Ai sr e s p o n s i b l ef o rd a m a g et o
the stomach lining.
ASA and also GCs activate the ALX/FRP2 receptor,
making them the ideal collaborator in the resolution
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Page 7 of 14process [77]. GCs-induced annexin-1 protein (ANXA1)
[110,111] as well as ASA-induced ATLs act on the same
ALX/FPR2 receptor and dampen PMN infiltration
[77,80]. ANXA1 also inhibits the phospholipids A2
enzyme (PLA2). Reduced PLA2 activity appears to
reduce AA release from the cell membrane [32,112],
which possibly leads to decreased levels of both PGs
and LTs and to the delay of resolution. Besides their
anti-inflammatory effects, GCs have a positive influence
on resolution by enhancing macrophage migration and
phagocytosis [11,113].
Adverse effects of medication on Resoleomics
The use of anti-inflammatory medication without the
capacity to induce (complete) resolution should be con-
sidered solution-toxic, ie hindering Resoleomics. NSAIDs
are strong inhibitors of COX-2 and less of COX-1
enzymes [114]. Almost complete COX-2 inhibition
decreases the PGs synthesis, and consequently leads to a
higher production of LTs via LOX-5 in PMNs [115].
PGE2 and PgD2 decrease the activity of LOX-5, decreas-
ing neutrophil activity and facilitating the end of the
inflammatory phase and the instigation of resolution.
Immune-suppressors such as SSZ (and less powerful
GCs) almost completely block NF-kB transcription,
leading to insufficient cytokine production and subopti-
mal inflammation [86]. Again the resolution process will
not be completed, with perpetuation of inflammation as
the logical consequence.
Perhaps the most deleterious drugs, interfering nega-
tively with resolution, are TNF-alpha inhibitors such as
anti TNF-alpha and MTX. MTX inhibits the proliferation
of the IIS cells, decreasing the production and accumula-
tion of adenosine within the IS cells [88,116]. These effects
lead to rapid anti-inflammatory effects and symptom
release. However, because of its side effects and incom-
plete resolution, this medication is qualified as solution-
toxic. This conclusion is supported by many patients who
have discontinued this treatment [73].
Another group of possible solution-toxic drugs are biolo-
gical agents with an inhibiting effect on TNF-alpha and IL-
1. Biological agents together with DMARDS (Table 1) are
strong anti-inflammatory compounds, decreasing the pro-
duction of pro-inflammatory cytokines. The absence or
insufficient activity of pro-inflammatory cytokines
decreases cell communication and induction of COX-2 in
activated neutrophils. This can lead to less production of
resolution substances such as PgE2, PgD2 and lipoxins
[54,103]. Furthermore, DMARDs and biological agents
appear to reduce the functioning and number of IIS cells,
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Figure 5 High glycemic food intake could cause inflammation and diseases as a result of hyperinsulinemia. The pathways in the shaded
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Page 8 of 14causing suboptimal inflammation and possibly inflamma-
tion perpetuation [104].
Discussion
Long-term activity of the IIS results in low-grade
inflammation and chronic disease. Over the past years,
ideas regarding the treatment of inflammation have
started to change as evidence accumulates which shows
that, although the targeting of infiltrating immune cells
can control the inflammatory response, it does not lead
to its complete resolution and a return to homeostasis,
which is essential for healthy tissue and good health in
general.
Hotamisligil describes how low-grade, chronic inflam-
mation (’meta-inflammation’) induced by a nutritional
and metabolic surplus, is accompanied by disturbed
metabolic pathways and chronic metabolic disorders. He
states that this inflammatory response differs from the
classical inflammation response caused by injury [117].
However, others have shown that the classical response
of the IIS dealing with injuries can be linked to activation
of the central stress axes [26,28]. This article specifically
discusses the relationship between the over-activated sys-
temic stress system and the self-limited process of
inflammation, known as Resoleomics, executed and con-
trolled by the innate immune system (IIS).
Table 1 Current RA treatments and their effect on immune system cells and predicted effect on Resoleomics
Medication Mechanism of action Current RA treatment effects on
Immune System Cells
Predicted effects on
ResoleomicsPhase 1: initiation, Phase
2: resolution, Phase 3: termination
Aspirin (ASA)
[11,14,32,77-83]
COX-1 inhibition, COX-2 acetylationPGE2
↓ATLs (15-epi-LX) ↑Activation of the
ALX/FPR2 receptor ↑PLA2 ↓: free AA,
PGE & LT ↓
PMN infiltration ↓, PGEs ↓, chemokines
↓Leucocyte accumulation ↓Neutrophil
recruitment ↓Vascular permeability
↓Nonphlogistic phagocytosis of
apoptoticneutrophils ↑
Negative: PG < LT levels: Phase 1
↑Positive: PG not completely ↓: switch
from phase 1 to phase 2 ↑Positive: ATLs
↑: phase 2 ↑ and 3 ↑
NSAIDs:COX-
inhibitors [84,85]
COX-2 inhibition > COX-1 inhibitionPGE2
↓, LTB4 ↑PGF2a, PGD2 ↓
COX-2 expression macrophages ↓:
Chemotaxis of neutrophils, eosinophils
and monocytes into synovium ↓
Negative: PG < LTB4 levels: Phase 1
↑Switch from phase 1 to 2 ↓Switch from
phase 2 to 3 ↓
Glucocorticosteroid
(GCs)[32,80,86,87]
Transcription of IKB ↑: NFkB
↓Transcription by GCR &CREB-binding
protein (CBP) ↓PLA2 ↓: free AA, PGE & LT
↓Annexin-1 ↑Activation of the ALX/FPR2
receptor ↑
PMN infiltration ↓, PGEs ↓, chemokines
↓Leucocyte accumulation ↓Neutrophil
recruitment ↓NFkB - transcription
↓Expression of inflammatory genes
↓Macrophage migration and
phagocytosis ↑
Negative: PGE, LT ↓: switch from phase 1
to 2 ↓Cortisol resistance: switch from
phase 1 to phase 2 ↓ or no
switchLipoxins ↓: switch from phase 2 to
3 ↓
DMARDs:
Methotrexate MTX
[88-102]
Folate analogs:1. Folate-dependent
enzymes ↓:1a. Thymidylate synthetase1b.
AICAR transformylase1c. Dihydrofolate
reductase2. Cytosol peroxide (ROS) ↑
Ad 1a. Synthesis of DNA & RNA ↓T-cell-
proliferation & protein- & cytokine-
expression by T-cells ↓, LT & IL-1 ↓Ad 1b.
Adenosine ↑: NK-cell, monocytes &
macrophages functioning↓, Cytokine
synthesis of TNF-a, IL-1, IL-6 & IL-8 ↓
1c. THF ↓: purine &
pyrimidine ↓Ad 2.
T-cell apoptosis ↑
Negative: cytokines, T-cell activity ↓,L T↓:
switch from phase 1 to 2 ↓ or no switch
DMARDs:
Sulphasalazine (SSZ)
[86]
SSZ: strong and potent inhibitor of
NFkB-activation5-amino acytelate (5-
ASA): PG ↓sulpha-pyridine
Less NFkB activation ↓: IL-2 of activated
T-cells ↓, TNF alfa & IL-1 macro-phages ↓,
Antibody in plasma cells ↓, Neutrophils,
monocytes, macrohages, granulocyte
activation ↓, IKB ↓: NFkB translocation ↓
& transcription of cytokines, adhesion
molecules, chemokines ↓: COX-2 & PG↓
Negative: Immune cell activity ↓: switch
from phase 1 to 2 ↓
Biological agents:
Anti TNF-alpha
[54,103-105]
TNF-alfa signalling of mono’s, PMN’s, T-
cells, endothelial cells, synovial fibroblasts
& adipocytes ↓COX-2 induction ↓
Monocyte activation, cytokine & PG
release ↓PMN priming, apoptosis and
oxidative burst; T-cell apoptosis, clonal
regulation & T-cell receptor ↓Endothelial-
cell adhesion molecule expression,
cytokine release ↓synovial fibroblast
proliferation, collagen synthesis, MMP &
cytokine release ↓Adipocyte FFA release
↑
Negative: Immune cell activity ↓: switch
from phase 1 to 2 ↓
Biological agents:IL-
1 blocker
[54,103-105]
IL-1 signalling of monocytes, B-cells,
endothelial cell, synovial fibroblasts,
chrondrocytes ↓COX-2 induction ↓
Synovial fibroblast cytokine, chemokine,
MMP, iNOS & PG release ↓Mono’s
cytokine, ROI & PG release ↓Osteoclast
activity ↑GAG synthesis ↓, iNOS ↑, MMP
& aggrecanaseEndothelial-cell adhesion
molecule expression↓
Negative: Immune cell activity ↓: switch
from phase 1 to 2 ↓
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process should be consideredam a j o rt r i g g e ri nc a u s i n g
chronic activation of the IS and consequently of the cen-
tral stress axes and vice versa, thereby leading to chronic
diseases such as cardiovascular diseases (CVD), diabetes,
respiratory diseases, mental disorders, auto-immune dis-
eases (AID) and cancers. This article evaluates two of the
lifestyle changes which contribute to long-term activity of
the ISS, namely, nutrition and continuous psycho-emo-
tional stress. Other risk factors such as physical inactivity
[6], genetic susceptibility [118], smoking, environmental
toxicity and shift work [119] fall beyond the scope of this
article but should not be ruled out.
Nutrition is an important factor in understanding the
development of chronic inflammation. The current Wes-
tern diet can disturb the resolution response in various
ways (Figure 6). In the Ancestral human diet, foodstuffs
with an increased risk of inflammation were virtually
unknown, while nutrients able to activate the IIS are now
abundant in our diet [38,120]. Cordain’s research has
focused on relating these anti-nutrients in food (eg lec-
tines, saponines) to the development of chronic inflamma-
tion and autoimmune diseases (AID) [7,39]. Fortunately, it
seems that the human body possesses a strong capacity to
recover from illness. If our genes are exposed to their ‘ori-
ginal’ environment by intake of an ancestral human diet,
their function can recover rapidly. Research has shown
that obese persons improve their blood markers after just
10 days following a paleolithic diet consisting of fish, lean
meat, fruit, vegetables and nuts [121]. Similar results have
been found in a study with aboriginals suffering from
Diabetes II, who showed normalized blood markers after
returning to their traditional lifestyle for seven weeks
[122].
People suffering from chronic inflammatory disease
demonstrate over-activated central stress axes, which then
lead to catecholamines, cortisol and insulin resistance.
McGowan et al [123] show the impact of childhood abuse
on the epigenetic pattern of different genes including the
gene for GR in the hippocampus. They found a decreased
level of GR and an increased methylation pattern of the
GR gene, giving rise to a situation of lower cortisol sensi-
bility and altered HPA stress responses. This could make
people more vulnerable to developing diseases. An altered
sensitivity to cortisol has been linked to diseases such as
rheumatoid arthritis (RA) [124], post-traumatic stress syn-
drome [125], chronic fatigue syndrome [126], inflamma-
tory diseases and AID in general [127].
The key priority in the treatment of people with
chronic inflammation is to induce the Eicosanoid Switch
to the anti-inflammatory resolution phase. Long-lasting
cortisol resistance and insulin resistance will definitely
delay or block complete resolution. The combination of
local factors (ie DHA deficiency, low levels of protectins)
disturbing the process of complete resolution (ie Resoleo-
mics) and the absence of adequate NE and cortisol
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Figure 6 Reflection of the working mechanism demonstrating how several nutritional factors could induce and inhibit inflammation.
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Page 10 of 14signalling can be responsible for perpetuatual inflamma-
tion by delaying the resolution phase of the inflammatory
response (Figure 7).
Current anti-inflammatory medication used in RA treat-
ment is aimed at the suppression of the IIS and its inflam-
matory response and thus hinders Resoleomics. In
addition, these medication interventions do not solve
underlying catecholamine, cortisol and insulin resistance,
and consequently making it impossible to achieve full
recovery of the chronic inflammation. This suggests that
chronic use of anti-inflammatory medication in fact
impedes the body from making a full recovery. Further-
more, the ongoing low-grade inflammation will continu-
ously trigger the activity of the systemic stress system [28].
Health care should focus on early detection of silent,
ongoing and low-grade inflammation in order to avoid the
development of many chronic diseases. Further research is
needed to validate a questionnaire which addresses early
symptoms of chronic low-grade inflammation, ie avoid-
ance of exercise, fatigue, emotional flatness, social isola-
tion, decreased libido, hyper or hyposomnia, obsessive
behaviour or sensitivity to addiction [6,128].
We have made an effort to demonstrate that the
science of Resoleomics can help to find new ways to treat
people suffering from diseases based on chronic inflam-
mation. Since over-activated central stress axes directly
delay Resoleomics, and thereby delay the resolution of
inflammation, treatment should focus on restoring the
central stress system to its default, healthy homeostasis.
Dietary changes, psycho-emotional stress release and
physical activity should always be included in treatment
of all chronic inflammatory diseases.
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